Bristol Myers Squibb's dividend sustainability faces a key test in 2027 amid patent losses on top drug Eliquis.

Bristol Myers Squibb has raised its dividend for 17 consecutive years, supported by strong free cash flow. However, the company faces a major challenge starting in 2027 when patent expiration on its top drug Eliquis will cause a significant revenue drop. While current cash flow comfortably covers dividends, the 2027 patent cliff and delayed drug replacements like Milvexian could strain cash flow and dividend payments. Investors will watch the 2026 full-year cash flow and dividend declarations closely for signs of sustainability beyond 2027.

Bristol Myers Squibb's long streak of dividend increases is under scrutiny as the company approaches a critical patent expiration in 2027. On Pluang, BMY shares trade at USD 63.04 with a slight 0.29% gain as of Sep 30, 2026, 23:01 WIB. The stock offers a dividend yield of 4.01%, and investor sentiment remains strongly positive with 95% of orders to buy. This data highlights ongoing investor interest despite upcoming challenges.